Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
Rhea-AI Summary
Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.
When: February 11, 2026 at 12:30 p.m. ET. Participants: Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer. A live and archived webcast will be available on the company's investor relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction – TENX
In the Feb 4 session, TENX gained 1.39%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 17 | Phase 3 design update | Positive | +5.7% | LEVEL Phase 3 BSSR confirmed >90% power and launch of LEVEL-2 trial. |
| Nov 25 | Investor conferences | Neutral | +4.4% | Announcement of two early-December healthcare conference fireside chats. |
| Nov 12 | Earnings and update | Neutral | -0.7% | Q3 2025 results, LEVEL timelines, patent progress, and cash runway to 2027. |
| Nov 06 | KOL call announcement | Neutral | -2.4% | Planned virtual KOL event to discuss TNX-103 and Phase 3 program. |
| Nov 03 | Guggenheim conference | Neutral | -2.3% | Participation in Guggenheim healthcare conference via fireside chat in Boston. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
TENX has shown modest, generally aligned price moves around clinical and event-driven updates, with conferences sometimes drawing positive interest.
Over the last few months, Tenax reported multiple late-stage development milestones for TNX-103 and maintained active investor engagement. A Dec 17 blinded sample size reassessment confirmed >90% power for the Phase 3 LEVEL trial and launch of LEVEL-2, which coincided with a +5.65% move. Earlier, Q3 2025 results on Nov 12 highlighted cash of $99.4M and runway through 2027. Participation in several investor conferences in Nov–Dec 2025 produced modest but generally aligned reactions, providing context for today’s Guggenheim summit appearance.
Key Terms
phase 3 medical
cardiopulmonary medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY.
Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer; Douglas Randall, Chief Business Officer
Date and Time: February 11, 2026, at 12:30 p.m. ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
